Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.83 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.83 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.61 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15980541 | 0.91 | HSP90AA1 (0.81) | HSP90AA1HSP90B1TRAP1ERBB2HSP90AB1 | |
| SCHEMBL4135031 | 0.91 | HSP90AA1 (1.00) | HSP90AA1HSP90B1TRAP1ERBB2HSP90AB1 | |
| SCHEMBL15980522 | 0.91 | HSP90AA1 (0.81) | HSP90AA1HSP90B1TRAP1ERBB2HSP90AB1 | |
| SCHEMBL4994869 | 0.91 | HSP90AA1 (1.00) | HSP90AA1HSP90B1TRAP1ERBB2HSP90AB1 | |
| SCHEMBL17449251 | 0.91 | HSP90AA1 (0.81) | HSP90AA1HSP90B1TRAP1ERBB2HSP90AB1 | |
| SCHEMBL18534343 | 0.88 | HSP90AA1 (0.83) | HSP90AA1HSP90B1TRAP1HSP90AB1 | |
| SCHEMBL15980472 | 0.87 | HSP90AA1 (0.72) | HSP90AA1HSP90B1 | |
| SCHEMBL15980538 | 0.86 | HSP90AA1 (0.75) | HSP90AA1HSP90B1TRAP1ERBB2HSP90AB1 | |
| SCHEMBL18431832 | 0.85 | HSP90AA1 (0.90) | HSP90AA1HSP90B1TRAP1ERBB2HSP90AB1 | |
| SCHEMBL15980539 | 0.85 | HSP90AA1 (0.73) | HSP90AA1HSP90B1TRAP1ERBB2HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9555137-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-01-31 | — | — | US | disclosed |
| US-20140294725-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140242602-A1 | USES OF LABELED HSP90 INHIBITORS | CORNELL UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294725-A1 | USES OF LABELED HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90B1 2/4885TRAP1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.